Literature DB >> 19007692

Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.

Frank A Cuoco1, William H Spencer, Valerian L Fernandes, Christopher D Nielsen, Sherif Nagueh, J Lacy Sturdivant, Robert B Leman, J Marcus Wharton, Michael R Gold.   

Abstract

OBJECTIVES: The purpose of this study was to examine the effects of alcohol septal ablation (ASA) on ventricular arrhythmias among patients with obstructive hypertrophic cardiomyopathy (HCM), as measured by appropriate implantable cardioverter-defibrillator (ICD) discharges.
BACKGROUND: Alcohol septal ablation is an effective therapy for patients with symptomatic HCM. However, concern has been raised that ASA may be proarrhythmic secondary to the iatrogenic scar created during the procedure. The impact of ASA on ventricular arrhythmias has not been well described.
METHODS: This prospective study included 123 consecutive patients with obstructive HCM who underwent ASA and had an ICD implanted for primary prevention of sudden cardiac death (SCD). The ICDs were implanted based on commonly accepted risk factors for SCD in the HCM population. Data from ICD interrogations during routine follow-up were collected.
RESULTS: Nine appropriate ICD shocks were recorded over a mean follow-up of 2.9 years in the cohort, which had a mean of 1.5 +/- 0.9 risk factors for SCD. Using Kaplan-Meier survival analysis, the estimated annual event rate was 2.8% over 3-year follow-up. There were no significant differences in the incidence of risk factors between patients who did and did not receive appropriate shocks.
CONCLUSIONS: The annual rate of appropriate ICD discharges after ASA is low and less than that reported previously for primary prevention of SCD in HCM. This suggests that ASA is not proarrhythmic. Traditional SCD risk factors did not predict ICD shocks in this cohort.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19007692     DOI: 10.1016/j.jacc.2008.07.061

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  14 in total

1.  Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy.

Authors:  Angelos G Rigopoulos; Silke Daci; Barbara Pfeiffer; Konstadia Papadopoulou; Anna Neugebauer; Hubert Seggewiss
Journal:  Clin Res Cardiol       Date:  2016-06-06       Impact factor: 5.460

2.  Recommendations of the current guidelines for implantable cardioverter-defibrillator implantation in patients with hypertrophic cardiomyopathy: Debate still exists.

Authors:  Arya Aminorroaya; Ali Vasheghani-Farahani; Farzad Masoudkabir; Pegah Roayaei
Journal:  J Interv Card Electrophysiol       Date:  2020-07-25       Impact factor: 1.900

Review 3.  Hypertrophic cardiomyopathy in 2013: Current speculations and future perspectives.

Authors:  Georgios K Efthimiadis; Efstathios D Pagourelias; Thomas Gossios; Thomas Zegkos
Journal:  World J Cardiol       Date:  2014-02-26

4.  Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes.

Authors:  Carey Kimmelstiel; David C Zisa; Johny S Kuttab; Sophie Wells; James E Udelson; Benjamin S Wessler; Hassan Rastegar; Navin K Kapur; Andrew R Weintraub; Barry J Maron; Martin S Maron; Ethan J Rowin
Journal:  Circ Cardiovasc Interv       Date:  2019-07-12       Impact factor: 6.546

5.  Alcohol septal ablation: in which patients and why?

Authors:  Paolo Spirito; Jessica Rossi; Barry J Maron
Journal:  Ann Cardiothorac Surg       Date:  2017-07

Review 6.  Implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of outcomes and complications.

Authors:  Nelson Wang; Ashleigh Xie; Richard Tjahjono; David H Tian; Steven Phan; Tristan D Yan; Pietro Bajona; Kevin Phan
Journal:  Ann Cardiothorac Surg       Date:  2017-07

7.  The prevalence and the prognostic value of microvolt T-wave alternans in patients with hypertrophic cardiomyopathy.

Authors:  Ewa Trzos; Jarosław D Kasprzak; Maria Krzemińska-Pakuła; Tomasz Rechciński; Karina Wierzbowska-Drabik; Barbara Uznańska; Adam Śmiałowski; Tomasz Rudziński; Małgorzata Kurpesa
Journal:  Ann Noninvasive Electrocardiol       Date:  2011-07       Impact factor: 1.468

8.  The risk of non-sustained ventricular tachycardia after percutaneous alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy.

Authors:  Mariusz Klopotowski; Lidia Chojnowska; Lukasz A Malek; Renata Maczynska; Krzysztof Kukula; Marcin Demkow; Adam Witkowski; Maciej Dabrowski; Maciej Karcz; Rafal Baranowski; Beata Kusmierczyk-Droszcz; Mariusz Kruk; Jacek Jamiolkowski; Mariusz Kusmierczyk; Lukasz Szumowski; Witold Ruzyllo
Journal:  Clin Res Cardiol       Date:  2010-02-11       Impact factor: 5.460

9.  Hypertrophic cardiomyopathy and sudden cardiac death.

Authors:  Konstantinos I Stroumpoulis; Ioannis N Pantazopoulos; Theodoros T Xanthos
Journal:  World J Cardiol       Date:  2010-09-26

10.  Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy.

Authors:  Constantinos O'Mahony; Saidi A Mohiddin; Charles Knight
Journal:  Interv Cardiol       Date:  2014-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.